A Phase 3 Open-Label Randomized Study to Compare the Efficacy And Safety of Rituximab Plus lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy in Subjects with Previously Untreated Follicular Lymphoma

Grants and Contracts Details

StatusFinished
Effective start/end date4/12/128/21/23

Funding

  • Celgene: $195,618.00